GSK, Gates Foundation Seek Heat-Stable Adjuvants for Vaccines - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

GSK, Gates Foundation Seek Heat-Stable Adjuvants for Vaccines


GlaxoSmithKline (GSK) and the Bill & Melinda Gates Foundation (BMGF) announced a joint initiative that will endeavor to make vaccines more resistant to heat, thus reducing the need for refrigeration. GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability. GSK researchers will explore how to make adjuvants, a critical component of some vaccines, more heat stable.

“Developing a thermostable adjuvant is an important and ambitious goal. This partnership is the starting point for research into an exciting area of biomedical technology that has the potential to overcome a significant and long-standing barrier to vaccine access in developing countries,” commented Emmanuel Hanon, Senior Vice President, Vaccine Discovery and Development, GSK. “At GSK, we believe that by working together we will find innovative solutions to the world’s biggest health problems.”

The project will focus initially on the adjuvant AS01 which is used in GSK’s RTS,S malaria vaccine candidate, currently in late-stage development in partnership with the PATH Malaria Vaccine Initiative. RTS,S has been designed for use in infants and children from sub-Saharan Africa, where maintaining vaccines at an optimum temperature can be challenging. Developing a method of making AS01 more heat stable could bring a significant public health benefit. The results could also have broader applications for all other AS01-containing vaccines, including vaccines in development by GSK against HIV and tuberculosis.

The Vaccine Discovery Partnership (VxDP), instigated by the BMGF, aims to integrate key players in vaccine development – biotechnology institutions, pharmaceutical companies, non-government organizations (NGOs) and academia – to drive advances in vaccine research and development (R&D) that have the potential to transform global health. Projects funded through the VxDP will look to solve some of the world’s most intractable health problems, including barriers to vaccine access.

Source: GlaxoSmithKline

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here